By manufacturing ibogaine, MINDCURE’s research team will have access to a predictable and standardized supply of synthetic ibogaine while ensuring consistent dosing and reliable results. VANCOUVER, BC, June 3, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( “MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics…


Previous articleCOMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
Next articleOp-ed: UK Public Support Psilocybin Research & Rescheduling Despite Government Stance